Skip to content
FCF Fox Corporate Finance GmbH
FCF Fox Corporate Finance GmbH
  • About FCF
    • Business
    • History
    • Facts & Figures
    • Philosophy
  • Business Units
    • FCF MidCap
    • FCF SmallCap / Growth
    • FCF DeepTech
    • FCF Life Sciences
  • Team
    • Team
    • Career
  • References
    • Transactions
    • Testimonials
  • Research
    • FCF Mid/SmallCap Sector Research
      • FCF Automotive Supplier Market Study
      • FCF European Chemicals Market Study
      • FCF Forestry, Paper & Packaging Market Study
      • FCF Industrial Machinery Market Study
      • FCF European Infrastructure & Construction Market Study
      • FCF Logistics & Transportation Market Study
      • FCF Metals & Materials Market Study
      • FCF European Pharmaceutical Market Study
      • FCF TMT Market Study
      • FCF Recycling Services Market Study
    • FCF Mid/SmallCap Market Research
      • FCF Bank Monitor
      • FCF Interest & Corporate Loan Monitor
      • FCF IPO Market Monitor
      • FCF Valuation Monitor
    • FCF DeepTech Research
      • FCF Advanced Manufacturing Venture Capital Report
      • FCF CleanTech Venture Capital Report
      • FCF IoT Venture Capital Report
      • FCF Robotics Venture Capital Report
    • FCF Life Sciences Research
      • FCF Life Sciences Venture Capital Monitor – Europe
      • FCF Biotech Venture Capital Monitor – USA
      • FCF Life Sciences Venture Capital Report
      • FCF Biotech Public Equity Monitor
      • FCF Life Sciences IPO Report
      • FCF Life Sciences SPAC Monitor
      • FCF MedTech & Diagnostics Public Equity Monitor
  • News & Events
    • Events
    • FCF Fremdkapital-Tag
    • MYFS
    • News
  • Contact
    • Subscribe newsletter
FCF Fox Corporate Finance GmbH
  • About FCF
    • Business
    • History
    • Facts & Figures
    • Philosophy
  • Business Units
    • FCF MidCap
    • FCF SmallCap / Growth
    • FCF DeepTech
    • FCF Life Sciences
  • Team
    • Team
    • Career
  • References
    • Transactions
    • Testimonials
  • Research
    • FCF Mid/SmallCap Sector Research
      • FCF Automotive Supplier Market Study
      • FCF European Chemicals Market Study
      • FCF Forestry, Paper & Packaging Market Study
      • FCF Industrial Machinery Market Study
      • FCF European Infrastructure & Construction Market Study
      • FCF Logistics & Transportation Market Study
      • FCF Metals & Materials Market Study
      • FCF European Pharmaceutical Market Study
      • FCF TMT Market Study
      • FCF Recycling Services Market Study
    • FCF Mid/SmallCap Market Research
      • FCF Bank Monitor
      • FCF Interest & Corporate Loan Monitor
      • FCF IPO Market Monitor
      • FCF Valuation Monitor
    • FCF DeepTech Research
      • FCF Advanced Manufacturing Venture Capital Report
      • FCF CleanTech Venture Capital Report
      • FCF IoT Venture Capital Report
      • FCF Robotics Venture Capital Report
    • FCF Life Sciences Research
      • FCF Life Sciences Venture Capital Monitor – Europe
      • FCF Biotech Venture Capital Monitor – USA
      • FCF Life Sciences Venture Capital Report
      • FCF Biotech Public Equity Monitor
      • FCF Life Sciences IPO Report
      • FCF Life Sciences SPAC Monitor
      • FCF MedTech & Diagnostics Public Equity Monitor
  • News & Events
    • Events
    • FCF Fremdkapital-Tag
    • MYFS
    • News
  • Contact
    • Subscribe newsletter

Press

Biotech Financing – Crisis? What Crisis? | European Biotechnology Winter Edition 2022/Volume 21 – Quotes by Arno Fuchs

In the Winter 2022 edition of “European Biotechnology“ magazine, from December, the cover story “Biotech Financing – Crisis? What Crisis?” focuses on 2022 as “the most difficult year for mergers and acquisitions in biotech since … Read more

Financing Situation – This will be expensive | Süddeutsche Zeitung 08.03.2022 – Quotes by FCF

Press Release

On March 8, 2022, the Süddeutsche Zeitung reports online about the current situation for medium-sized companies – supply bottlenecks and rising energy costs are showing their effects on medium-sized companies and also on consumers. Arno … Read more

IPO plans for magic-mushroom-holding: How good is the new project of German investor Christian Angermayer? | Handelsblatt 10.06.2021 – Quotes by FCF

On Thursday, June 10, the German newspaper “Handelsblatt” reported online and in its print version on the planned IPO of ATAI Life Sciences, a German company specializing in psychedelic drugs. Previously labeled as narcotic drugs, … Read more

FCF Life Sciences in the Börse Online magazine | 19. April 2021

FCF Life Sciences in the Börse Online magazine | 19. April 2021 The Life Sciences team at FCF Fox Corporate Finance has recently published an analysis on Special Purpose Acquisition Companies (SPACs) with a focus … Read more

FCF Life Sciences: Boom Bei Healthcare-SPACS Ungebrochen | GoingPublic 13.04.2021

Press Release

Der Boom um Special Purpose Acquisition Companies, auch SPACs genannt, setzt sich 2021 ungebremst fort. Lag die Zahl der SPAC-Börsengänge im gesamten Jahr 2020 noch bei 306 SPAC-IPOs, liegt sie in den ersten drei Monaten … Read more

CureVac – ein Weckruf für deutsche Investoren | GoingPublic 27.03.2020

Press Release

Der deutsche Markt erlebt hier seinen schonungslosen Moment der Wahrheit Dass die Corona-Krise besondere Entwicklungen mit sich bringt, ist in vielen Bereichen zu spüren. Die Auswirkungen der Ausbreitung des Virus sind in dieser Form noch … Read more

A gap with causes | Plattform Life Sciences 1/2020

DSD-Plattform-Life-Sciences-1-2020-FCF_Cover

German life science companies must raise more money abroad The fact that Germany’s life sciences industry is doing very well in European comparison is due to a few big deals. The latest venture capital research … Read more

Some disillusionment-but also a little bit of hope, Biotech in Bavaria–Report 2018/19

By Dr. Mathias Schott  and Sebastian Sommer To start off with the good news, Bavaria has proven its position within the German Biotech scene last year. The Free State accounted for an astonishing 40 percent of the German … Read more

Nicht nur im Bereich Life Sciences den Schneid abgekauft, GoingPublic Magazin: Plattform Life Sciences 04/18

Interview mit Arno Fuchs, CEO, FCF Fox Corporate Finance Die Plattform Life Sciences sprach mit Arno Fuchs über Deutschlands Life-Sciences-Branche im internationalen Vergleich, bedenkliche Entwicklungen und kostspielige (verpasste) Weichenstellungen. Plattform Life Sciences: Herr Fuchs, nimmt Deutschland … Read more

Millionen für das Wachstum, Holzkirchener Merkur 01/18

Older posts
Page1 Page2 Next →

Unsere letzten Beiträge

  • FCF Valuation Monitor – Q1 2023 published
  • Venture Capital Sentiment Tracker – April 2023
  • Life Sciences Venture Capital Monitor – Europe 04/2023 published
  • FCF Industrial Machinery Market Study – 2023
  • FCF Recycling Services Market Study – 2023 published
  • FCF Biotech Venture Capital Monitor – USA 03/2023 published
  • Venture Capital Sentiment Tracker – March 2023
  • Life Sciences Venture Capital Monitor – Europe 03/2023 published
  • FCF Bank Monitor – Q1 2023 published
  • Venture Capital Sentiment Tracker – February 2023
FCF Fox Corporate Finance GmbH • Maximilianstr. 12-14 • 80539 Munich, Germany • T: +49-89-20 60 409-0 • Imprint • Data Protection • LinkedIn • Xing
Scroll Up